Patients who start their blood pressure treatment with angiotensin receptor blocker (ARB) drugs continue with the same medicine to a greater extent than patients who start out with other drugs. Choosing the right drug from the outset can therefore improve both health and quality of life—as well as bringing down health care costs. This is shown in a new study based on data from 340,000 patients. The research is published in the journal eClinicalMedicine.
This article was originally published on MedicalXpress.com
